@spider109 Here's an excerpt about future directions in the treatment of bronchiectasis (from 2022). It still has a bit to go, maybe 2025 if it passes all the hurtles.

"Treatments that target neutrophils may have an important role to play in the treatment of bronchiectasis. A recent phase 2 trial of brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1, showed promising results in patients with a history of two or more exacerbations in the year before trial enrollment. The time until the next exacerbation was longer with brensocatib than with placebo, with an acceptable side-effect profile. A phase 3 trial of brensocatib is currently under way. Other potential therapeutics being considered in bronchiectasis include novel inhibitors of dipeptidyl peptidase 1, antagonism of CXC chemokine receptor 2, and immunomodulatory drugs, including those that target eosinophils."